Q4 2022 Results

Company overview Financial review 2023 priorities Appendix Confidence in near and mid-term growth underpinned by multi-bn existing medicines and pipeline GROWTH Existing large multi-bn medicines1, USD 13.2bn growing 26% (FY22) Additional multi-bn¹ medicines Select pipeline with multi-bn¹ potential KISQALI zolgensma PLUVICTO™ SCEMBLIX iptacopan (R) Cosentyx Entresto Kesimpta LEQVIO® IN-MARKET remibrutinib pelacarsen ianalumab Additional pipeline assets NEAR-TERM Expected LOE impact greater up to 2025, less thereafter² MID-TERM 1. Potential USD sales. 2. For forecasting purposes, we assume Entresto LOE in 2025. 21 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation